Source: Eur Respir J 2016; 47:1481-1491
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Raghu Ganesh, Scholand Mary Beth, de Andrade João, Lancaster Lisa, Mageto Yolanda, Goldin Jonathan, Brown Kevin K., Flaherty Kevin R., Wencel Mark, Wanger Jack, Neff Thomas, Valone Frank, Stauffer John, Porter Seth. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47:1481-1491

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020 Year: 2021 Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 Results of a randomized, double blind trial of anti-tumor necrosis antibody for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma Source: Eur Respir J 2013; 41: 330-338 Year: 2013 Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019 SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018 Serum anti DFS70 antibody titer and lung functional impairment in patients with interstitial lung disease (ILD) Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011